Regencell Bioscience (RGC) has released an update.
Regencell Bioscience Holdings Limited reported a notable reduction in its net loss for the first half of 2024, decreasing by 34% to $2.2 million compared to the same period in 2022. This improvement was primarily due to a significant decrease in operating expenses across selling, marketing, general and administrative, and research and development sectors. Additionally, the company experienced an increase in cash to $4.8 million, bolstered by investment proceeds and interest income.
For further insights into RGC stock, check out TipRanks’ Stock Analysis page.
